GLYCOMINE
Glycomine is early-stage biotech working on replacement therapies for rare diseases. There are approximately 7,000 rare disorders worldwide. Each day more are being discovered. 95% of rare diseases have not one single FDA-approved treatment. Glycomine develops therapeutics for diseases that have no treatment options.
GLYCOMINE
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2013-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.glycomine.com
Total Employee:
1+
Status:
Active
Contact:
(415)617-5755
Total Funding:
80 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
AcertaPharma
Acerta Pharma provides drug discovery and development services for oncology and autoimmune diseases.
AZTherapies
AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Current Advisors List
Advisor
Board_member
2021-06-23
Board_member
2021-06-23
Board_member
2021-06-23
Current Employees Featured
Peter McWilliams CEO @ Glycomine
CEO
Steven Axon Chief Executive Officer @ Glycomine
Chief Executive Officer
2022-06-01
Horacio Plotkin Chief Medical Officer @ Glycomine
Chief Medical Officer
2020-03-01
Deirdre Foley Director of R&D, Biology @ Glycomine
Director of R&D, Biology
2016-10-01
Founder
Investors List
Mission BioCapital
Mission BioCapital investment in Series B - Glycomine
Sanofi Ventures
Sanofi Ventures investment in Series B - Glycomine
Remiges Ventures
Remiges Ventures investment in Series B - Glycomine
Chiesi Ventures
Chiesi Ventures investment in Series B - Glycomine
RiverVest
RiverVest investment in Series B - Glycomine
Novo Holdings
Novo Holdings investment in Series B - Glycomine
Abingworth
Abingworth investment in Series B - Glycomine
Sanderling Ventures
Sanderling Ventures investment in Series B - Glycomine
Asahi Kasei
Asahi Kasei investment in Series B - Glycomine
Asahi Kasei
Asahi Kasei investment in Series B - Glycomine
Official Site Inspections
http://www.glycomine.com Semrush global rank: 4.76 M Semrush visits lastest month: 1.94 K
- Host name: 155.250.226.35.bc.googleusercontent.com
- IP address: 35.226.250.155
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Glycomine"
Therapeutics For Serious Rare Diseases | About …
Glycomine is committed to developing therapeutics for serious rare diseases, the vast majority of which do not have any disease-modifying treatment options available. There are approximately 7,000 rare disorders worldwide. Each day …See details»
Glycomine - Crunchbase Company Profile & Funding
Organization. Glycomine . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Glycomine …See details»
Glycomine Inc. - LinkedIn
Glycomine’s lead drug candidate, GLM101, is a novel substrate replacement therapy in development to treat phosphomannomutase 2-congenital disorder of glycosylation (PMM2 …See details»
Glycomine 2025 Company Profile: Valuation, Funding & Investors
Glycomine General Information Description. Developer of orphan drugs designed to treat rare disorders of metabolism and protein misfolding. The company's drugs combine replacement …See details»
Glycomine - Org Chart, Teams, Culture & Jobs | The Org
View Glycomine's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Glycomine | Advent Life Sciences
Glycomine is committed to developing therapeutics for serious rare diseases, the vast majority of which do not have any disease-modifying treatment options available. Its lead program, …See details»
Glycomine Company Profile - Office Locations, Competitors ... - Craft
Glycomine is a company that develops therapeutics for diseases without treatment options. It focuses on genetic disorders of protein and lipid glycosylation, The company addresses …See details»
Glycomine, Inc. - RiverVest
10996 Torreyana Road, Suite 280 San Diego, CA 92121. Phone: (314) 726.6700See details»
Glycomine - VentureRadar
Glycomine is developing orphan drugs for serious rare monogenic disorders of metabolism and protein misfolding for which no other therapeutic options exist. The company's approach is to …See details»
Glycomine Raises $115M for Phase IIb of Genetic Glycosylation …
3 days ago Glycomine’s late-stage program represents a financial and clinical beacon in a challenging macroeconomic environment, especially for rare disease companies. With this …See details»
Glycomine - Pappas Capital
Sep 18, 2024 Glycomine is a drug development company focused on developing therapeutics for the treatment of a group of inherited metabolic disorders collectively known as congenital …See details»
Glycomine Announces $115 Million Series C Financing to Advance …
3 days ago Glycomine is a clinical-stage biotechnology company that is advancing treatments for serious rare diseases for which no other therapeutic options exist. The Company’s lead …See details»
Startup Glycomine raises $115M to push rare disease drug deeper …
3 days ago Glycomine, a biotechnology startup working on a treatment for a rare genetic disorder, has raised a $115 million Series C round to push its lead program deeper into clinical …See details»
Glycomine Gets $115M Series C for Rare Disease, Aims for
2 days ago California-based biopharma Glycomine announced a $115 million Series C raise Wednesday to push its lead rare disease molecule into Phase IIb trials. “We’re working on …See details»
Wilson Sonsini Advises Glycomine on $115 Million Series C
3 days ago On April 16, 2025, Glycomine, a biotechnology company focused on developing transformative new therapies for orphan diseases, announced a $115 million Series C …See details»
Glycomine raises $115m to advance rare disease therapy into …
3 days ago In parallel to Glycomine’s programme, a separate effort is underway to assess the potential of a repurposed therapy for PMM2-CDG. Maggie’s Pearl – a joint venture between …See details»
Glycomine gears up for potentially pivotal rare disease study with ...
3 days ago Glycomine is planning a mid-year launch for the Phase IIb study of GLM101, a first-in-class mannose-1-phosphate replacement therapy. For the first six months of the study, half …See details»
Startup Glycomine Lands $115M for Clinical Trial in Ultra-Rare …
3 days ago Glycomine is developing a drug that takes a novel approach to the enzyme deficiency. On Wednesday, the San Carlos, California-based biotech announced $115 million …See details»
Glycomine raises $115M to target rare glycosylation disorder
2 days ago Glycomine raises $115M Series C to advance GLM101, a mannose-1-phosphate therapy for PMM2-CDG rare disease, toward Phase 2b trial and potential FDA filing next year.See details»
Glycomine's $115M series C to fund genetic disorder ph. 2 plans
2 days ago Glycomine's latest fundraise follows a $12 million series A in 2016 and a $68 million series B spread across 2019 and 2021. Other players in the PMM2-CDG space are assessing …See details»